Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors
Marja D. Van Sickle,1*
Marnie Duncan,1*
Philip J. Kingsley,2
Abdeslam Mouihate,1
Paolo Urbani,3
Ken Mackie,4
Nephi Stella,5
Alexandros Makriyannis,6
Daniele Piomelli,7
Joseph S. Davison,1
Lawrence J. Marnett,2
Vincenzo Di Marzo,3
Quentin J. Pittman,1
Kamala D. Patel,1
Keith A. Sharkey1
Abstract:
The presence and function of CB2 receptors in central nervoussystem (CNS) neurons are controversial. We report the expressionof CB2 receptor messenger RNA and protein localization on brainstemneurons. These functional CB2 receptors in the brainstem wereactivated by a CB2 receptor agonist, 2-arachidonoylglycerol,and by elevated endogenous levels of endocannabinoids, whichalso act at CB1 receptors. CB2 receptors represent an alternativesite of action of endocannabinoids that opens the possibilityof nonpsychotropic therapeutic interventions using enhancedendocannabinoid levels in localized brain areas.
1 Institute of Infection, Immunity, and Inflammation and Hotchkiss Brain Institute, Department of Physiology and Biophysics, University of Calgary, Calgary, AB, Canada T2N 4N1. 2 Department of Biochemistry, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 372320146, USA. 3 Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Naples, Italy. 4 Department of Anesthesiology and Department of Physiology and Biophysics, University of Washington, Seattle, WA 981956540, USA. 5 Department of Pharmacology, Psychiatry, and Behavioral Sciences, University of Washington, Seattle, WA 981957280, USA. 6 Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. 7 Department of Pharmacology, Gillespie Neuroscience Facility, University of California, Irvine, CA 926976180, USA.
* These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail: ksharkey{at}ucalgary.ca
The editors suggest the following Related Resources on Science sites:
Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease.
J. Bouchard, J. Truong, K. Bouchard, D. Dunkelberger, S. Desrayaud, S. Moussaoui, S. J. Tabrizi, N. Stella, and P. J. Muchowski (2012)
J. Neurosci.
32, 18259-18268
|Abstract »|Full Text »|PDF »
Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain.
L. Callen, E. Moreno, P. Barroso-Chinea, D. Moreno-Delgado, A. Cortes, J. Mallol, V. Casado, J. L. Lanciego, R. Franco, C. Lluis, et al. (2012)
J. Biol. Chem.
287, 20851-20865
|Abstract »|Full Text »|PDF »
Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System.
M. Naguib, J. J. Xu, P. Diaz, D. L. Brown, D. Cogdell, B. Bie, J. Hu, S. Craig, and W. N. Hittelman (2012)
Anesth. Analg.
114, 1104-1120
|Abstract »|Full Text »|PDF »
Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors.
F. S. den Boon, P. Chameau, Q. Schaafsma-Zhao, W. van Aken, M. Bari, S. Oddi, C. G. Kruse, M. Maccarrone, W. J. Wadman, and T. R. Werkman (2012)
PNAS
109, 3534-3539
|Abstract »|Full Text »|PDF »
3-Substituted Pyrazole Analogs of the Cannabinoid Type 1 (CB1) Receptor Antagonist Rimonabant: Cannabinoid Agonist-Like Effects in Mice via Non-CB1, Non-CB2 Mechanism.
J. L. Wiley, D. E. Selley, P. Wang, R. Kottani, S. Gadthula, and A. Mahadeven (2012)
J. Pharmacol. Exp. Ther.
340, 433-444
|Abstract »|Full Text »|PDF »
Inhibition of Monoacylglycerol Lipase Attenuates Nonsteroidal Anti-Inflammatory Drug-Induced Gastric Hemorrhages in Mice.
S. G. Kinsey, D. K. Nomura, S. T. O'Neal, J. Z. Long, A. Mahadevan, B. F. Cravatt, J. R. Grider, and A. H. Lichtman (2011)
J. Pharmacol. Exp. Ther.
338, 795-802
|Abstract »|Full Text »|PDF »
Intrathecal Administration of the Cannabinoid 2 Receptor Agonist JWH015 Can Attenuate Cancer Pain and Decrease mRNA Expression of the 2B Subunit of N-Methyl-D-Aspartic Acid.
X. Gu, F. Mei, Y. Liu, R. Zhang, J. Zhang, and Z. Ma (2011)
Anesth. Analg.
113, 405-411
|Abstract »|Full Text »|PDF »
Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis.
J. L. Lanciego, P. Barroso-Chinea, A. J. Rico, L. Conte-Perales, L. Callen, E. Roda, V. Gomez-Bautista, I. P. Lopez, C. Lluis, J. L. Labandeira-Garcia, et al. (2011)
J Psychopharmacol
25, 97-104
|Abstract »|PDF »
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2.
R. G. Pertwee, A. C. Howlett, M. E. Abood, S. P. H. Alexander, V. Di Marzo, M. R. Elphick, P. J. Greasley, H. S. Hansen, G. Kunos, K. Mackie, et al. (2010)
Pharmacol. Rev.
62, 588-631
|Abstract »|Full Text »|PDF »
Energetic Metabolism and Human Sperm Motility: Impact of CB1 Receptor Activation.
A. Barbonetti, M. R. C. Vassallo, D. Fortunato, S. Francavilla, M. Maccarrone, and F. Francavilla (2010)
Endocrinology
151, 5882-5892
|Abstract »|Full Text »|PDF »
Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers.
K. Wesnes, P. Annas, C. Edgar, C. Deeprose, R. Karlsten, A. Philipp, J. Kalliomaki, and M. Segerdahl (2010)
J Psychopharmacol
24, 1659-1669
|Abstract »|PDF »
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist, Inhibits Gastrointestinal Motility but Has No Effect on Experimental Colitis in Mice.
N. L. Cluny, C. M. Keenan, M. Duncan, A. Fox, B. Lutz, and K. A. Sharkey (2010)
J. Pharmacol. Exp. Ther.
334, 973-980
|Abstract »|Full Text »|PDF »
The Role of Endocannabinoid Signaling in Motor Control.
Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain.
J. J. Xu, P. Diaz, F. Astruc-Diaz, S. Craig, E. Munoz, and M. Naguib (2010)
Anesth. Analg.
111, 99-109
|Abstract »|Full Text »|PDF »
A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor.
D. P. Hurst, A. Grossfield, D. L. Lynch, S. Feller, T. D. Romo, K. Gawrisch, M. C. Pitman, and P. H. Reggio (2010)
J. Biol. Chem.
285, 17954-17964
|Abstract »|Full Text »|PDF »
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment.
S. Murikinati, E. Juttler, T. Keinert, D. A. Ridder, S. Muhammad, Z. Waibler, C. Ledent, A. Zimmer, U. Kalinke, and M. Schwaninger (2010)
FASEB J
24, 788-798
|Abstract »|Full Text »|PDF »
Signaling Pathways from Cannabinoid Receptor-1 Activation to Inhibition of N-Methyl-D-Aspartic Acid Mediated Calcium Influx and Neurotoxicity in Dorsal Root Ganglion Neurons.
Q. Liu, M. Bhat, W. D. Bowen, and J. Cheng (2009)
J. Pharmacol. Exp. Ther.
331, 1062-1070
|Abstract »|Full Text »|PDF »
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.
Endocannabinoids Suppress Excitatory Synaptic Transmission to Dorsal Raphe Serotonin Neurons through the Activation of Presynaptic CB1 Receptors.
S. Haj-Dahmane and R.-Y. Shen (2009)
J. Pharmacol. Exp. Ther.
331, 186-196
|Abstract »|Full Text »|PDF »
Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain.
S. G. Kinsey, J. Z. Long, S. T. O'Neal, R. A. Abdullah, J. L. Poklis, D. L. Boger, B. F. Cravatt, and A. H. Lichtman (2009)
J. Pharmacol. Exp. Ther.
330, 902-910
|Abstract »|Full Text »|PDF »
Novel endogenous peptide agonists of cannabinoid receptors.
I. Gomes, J. S. Grushko, U. Golebiewska, S. Hoogendoorn, A. Gupta, A. S. Heimann, E. S. Ferro, S. Scarlata, L. D. Fricker, and L. A. Devi (2009)
FASEB J
23, 3020-3029
|Abstract »|Full Text »|PDF »
Selective CB2 Receptor Agonism Protects Central Neurons from Remote Axotomy-Induced Apoptosis through the PI3K/Akt Pathway.
M. T. Viscomi, S. Oddi, L. Latini, N. Pasquariello, F. Florenzano, G. Bernardi, M. Molinari, and M. Maccarrone (2009)
J. Neurosci.
29, 4564-4570
|Abstract »|Full Text »|PDF »
Endocannabinoid-Mediated Control of Synaptic Transmission.
M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, and M. Watanabe (2009)
Physiol Rev
89, 309-380
|Abstract »|Full Text »|PDF »
Divergent Effects of Anandamide Transporter Inhibitors with Different Target Selectivity on Social Play Behavior in Adolescent Rats.
V. Trezza and L. J. M. J. Vanderschuren (2009)
J. Pharmacol. Exp. Ther.
328, 343-350
|Abstract »|Full Text »|PDF »
Crucial Role of CB2 Cannabinoid Receptor in the Regulation of Central Immune Responses during Neuropathic Pain.
I. Racz, X. Nadal, J. Alferink, J. E. Banos, J. Rehnelt, M. Martin, B. Pintado, A. Gutierrez-Adan, E. Sanguino, J. Manzanares, et al. (2008)
J. Neurosci.
28, 12125-12135
|Abstract »|Full Text »|PDF »
Interferon-{gamma} Is a Critical Modulator of CB2 Cannabinoid Receptor Signaling during Neuropathic Pain.
I. Racz, X. Nadal, J. Alferink, J. E. Banos, J. Rehnelt, M. Martin, B. Pintado, A. Gutierrez-Adan, E. Sanguino, N. Bellora, et al. (2008)
J. Neurosci.
28, 12136-12145
|Abstract »|Full Text »|PDF »
N-Arachidonyl Maleimide Potentiates the Pharmacological and Biochemical Effects of the Endocannabinoid 2-Arachidonylglycerol through Inhibition of Monoacylglycerol Lipase.
J. J. Burston, L. J. Sim-Selley, J. P. Harloe, A. Mahadevan, R. K. Razdan, D. E. Selley, and J. L. Wiley (2008)
J. Pharmacol. Exp. Ther.
327, 546-553
|Abstract »|Full Text »|PDF »
Modulation of the Endocannabinoid System in Cardiovascular Disease: Therapeutic Potential and Limitations.
P. Pacher, P. Mukhopadhyay, R. Mohanraj, G. Godlewski, S. Batkai, and G. Kunos (2008)
Hypertension
52, 601-607
|Full Text »|PDF »
Identification of Novel Endogenous Cytochrome P450 Arachidonate Metabolites with High Affinity for Cannabinoid Receptors.
J.-K. Chen, J. Chen, J. D. Imig, S. Wei, D. L. Hachey, J. S. Guthi, J. R. Falck, J. H. Capdevila, and R. C. Harris (2008)
J. Biol. Chem.
283, 24514-24524
|Abstract »|Full Text »|PDF »
Endocannabinoid 2-Arachidonoylglycerol Protects Neurons by Limiting COX-2 Elevation.
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats.
M. Duncan, A. Mouihate, K. Mackie, C. M. Keenan, N. E. Buckley, J. S. Davison, K. D. Patel, Q. J. Pittman, and K. A. Sharkey (2008)
Am J Physiol Gastrointest Liver Physiol
295, G78-G87
|Abstract »|Full Text »|PDF »
Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells.
V. L. Hegde, S. Hegde, B. F. Cravatt, L. J. Hofseth, M. Nagarkatti, and P. S. Nagarkatti (2008)
Mol. Pharmacol.
74, 20-33
|Abstract »|Full Text »|PDF »
Characterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation.
F. Fezza, S. Oddi, M. Di Tommaso, C. De Simone, C. Rapino, N. Pasquariello, E. Dainese, A. Finazzi-Agro, and M. Maccarrone (2008)
J. Lipid Res.
49, 1216-1223
|Abstract »|Full Text »|PDF »
Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.
P. Pacher and Z. Ungvari (2008)
Am J Physiol Heart Circ Physiol
294, H1133-H1134
|Full Text »|PDF »
Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats.
J. Munoz-Luque, J. Ros, G. Fernandez-Varo, S. Tugues, M. Morales-Ruiz, C. E. Alvarez, S. L. Friedman, V. Arroyo, and W. Jimenez (2008)
J. Pharmacol. Exp. Ther.
324, 475-483
|Abstract »|Full Text »|PDF »
Hemopressin is an inverse agonist of CB1 cannabinoid receptors.
A. S. Heimann, I. Gomes, C. S. Dale, R. L. Pagano, A. Gupta, L. L. de Souza, A. D. Luchessi, L. M. Castro, R. Giorgi, V. Rioli, et al. (2007)
PNAS
104, 20588-20593
|Abstract »|Full Text »|PDF »
Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.
M. Rajesh, H. Pan, P. Mukhopadhyay, S. Batkai, D. Osei-Hyiaman, G. Hasko, L. Liaudet, B. Gao, and P. Pacher (2007)
J. Leukoc. Biol.
82, 1382-1389
|Abstract »|Full Text »|PDF »
A neutral CB1 receptor antagonist reduces weight gain in rat.
A. P. Chambers, V. K. Vemuri, Y. Peng, J. T. Wood, T. Olszewska, Q. J. Pittman, A. Makriyannis, and K. A. Sharkey (2007)
Am J Physiol Regulatory Integrative Comp Physiol
293, R2185-R2193
|Abstract »|Full Text »|PDF »
CB2-receptor stimulation attenuates TNF-{alpha}-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.
M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Hasko, L. Liaudet, J. W. Huffman, A. Csiszar, Z. Ungvari, K. Mackie, S. Chatterjee, et al. (2007)
Am J Physiol Heart Circ Physiol
293, H2210-H2218
|Abstract »|Full Text »|PDF »
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase.
S. Batkai, M. Rajesh, P. Mukhopadhyay, G. Hasko, L. Liaudet, B. F. Cravatt, A. Csiszar, Z. Ungvari, and P. Pacher (2007)
Am J Physiol Heart Circ Physiol
293, H909-H918
|Abstract »|Full Text »|PDF »
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
H. D. Burns, K. Van Laere, S. Sanabria-Bohorquez, T. G. Hamill, G. Bormans, W.-s. Eng, R. Gibson, C. Ryan, B. Connolly, S. Patel, et al. (2007)
PNAS
104, 9800-9805
|Abstract »|Full Text »|PDF »
Anandamide-Mediated CB1/CB2 Cannabinoid Receptor-Independent Nitric Oxide Production in Rabbit Aortic Endothelial Cells.
L. McCollum, A. C. Howlett, and S. Mukhopadhyay (2007)
J. Pharmacol. Exp. Ther.
321, 930-937
|Abstract »|Full Text »|PDF »
Endocannabinoids and Synaptic Function in the CNS.
Y. Hashimotodani, T. Ohno-Shosaku, and M. Kano (2007)
Neuroscientist
13, 127-137
|Abstract »|PDF »
Functional CB1 Receptors Are Broadly Expressed in Neocortical GABAergic and Glutamatergic Neurons.
E. L. Hill, T. Gallopin, I. Ferezou, B. Cauli, J. Rossier, P. Schweitzer, and B. Lambolez (2007)
J Neurophysiol
97, 2580-2589
|Abstract »|Full Text »|PDF »
A Novel Role of Cannabinoids: Implication in the Fever Induced by Bacterial Lipopolysaccharide.
K. Benamar, M. Yondorf, J. J. Meissler, E. B. Geller, R. J. Tallarida, T. K. Eisenstein, and M. W. Adler (2007)
J. Pharmacol. Exp. Ther.
320, 1127-1133
|Abstract »|Full Text »|PDF »
Cannabinoid receptors as novel targets for the treatment of melanoma.
C. Blazquez, A. Carracedo, L. Barrado, P. J. Real, J. L. Fernandez-Luna, G. Velasco, M. Malumbres, and M. Guzman (2006)
FASEB J
20, 2633-2635
|Abstract »|Full Text »|PDF »
J. Palazuelos, T. Aguado, A. Egia, R. Mechoulam, M. Guzman, and I. Galve-Roperh (2006)
FASEB J
20, 2405-2407
|Abstract »|Full Text »|PDF »
Effect of Lipid Rafts on Cb2 Receptor Signaling and 2-Arachidonoyl-Glycerol Metabolism in Human Immune Cells.
M. Bari, P. Spagnuolo, F. Fezza, S. Oddi, N. Pasquariello, A. Finazzi-Agro, and M. Maccarrone (2006)
J. Immunol.
177, 4971-4980
|Abstract »|Full Text »|PDF »
The Endocannabinoid System as an Emerging Target of Pharmacotherapy.
Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators.
H. B. Bradshaw, N. Rimmerman, J. F. Krey, and J. M. Walker (2006)
Am J Physiol Regulatory Integrative Comp Physiol
291, R349-R358
|Abstract »|Full Text »|PDF »